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Objectives
To determine the efficacy of a second treatment with a dif-
ferent TNF blocker in JIA when the first one failed.
Methods
All JIA patients prospectively followed at our Centre, who
failed a first TNF blocker and switched to a second one
were enrolled. For each patient the DAS, ACR Ped30,
ACR20, ACR50 and ACR70 responses were evaluated at
baseline and after a period ranging from 3 to 6 months of
each treatment.
Results
Out of 60 JIA patients enrolled, 40 (37 f, 3 m) were eval-
uated: 10 systemic arthritis, 2 persistent oligoarthritis, 11
extended oligoarthritis, 9 RF negative polyarthritis, 4 RF
positive polyarthritis, 1 ERA (enthesitis related arthritis),
3 psoriatic arthritis. With a standard Chi square model, we
didn't find a significant difference in the ACR and DAS
response rates between the first and the second anti TNF
treatment (p > 0.1). Stratifying the population for the type
of the shift (Etanercept to Infliximab/Adalimumab, Inflix-
imab to Etanercept/Adalimumab) we didn't find a signif-
icant difference in the ACR and DAS response rates
between the first and the second anti TNF treatment (p >
0.1). Our data show that failure of an anti-TNF therapy in
patients with JIA does not preclude a response to a second
anti-TNF agent of a different class.
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